AllSci News
Mirum's brelovitug aces Phase III in chronic hepatitis delta virus with 56% response rate
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that the Phase III portion of the AZURE-1 study of brelovitug, an anti-hepatitis B surface antigen (HBsAg)...
ADARx raises USD 446m in upsized Nasdaq IPO
San Diego-based ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million shares at USD 17 per share, raising approximately USD 446.3...
Carvykti sustains five-year remissions in half of early-line relapsed myeloma patients
Johnson & Johnson (NYSE: JNJ) reported five-year follow-up data from the Phase II CARTITUDE-2 study showing that half of patients with early-line relapsed...
Roche taps Atavistik Bio in USD 1.9bn allosteric drug discovery deal
Cambridge, Massachusetts-based Atavistik Bio entered a strategic research collaboration with Roche (OTCQX: RHHBY) to discover small-molecule therapies...
Tolerance Bio adds to thymus pipeline with anti-IL-33 antibody license from Tanabe
Philadelphia-based Tolerance Bio, Inc. has licensed TLB-33 (MT-2990), a clinical-stage anti-IL-33 monoclonal antibody, from Japan-based Tanabe Pharma...
Merck strikes USD 2.13bn deal for China-origin preclinical KRAS G12D inhibitor
Merck (NYSE: MRK) has agreed to pay USD 400 million upfront to exclusively license SPR2015, a preclinical oral KRAS G12D-targeted RAS(ON) inhibitor from...
AstraZeneca wins Priority Review for Imfinzi-EV regimen in bladder cancer
The US FDA granted Priority Review to AstraZeneca’s supplemental BLA for perioperative Imfinzi (durvalumab) with neoadjuvant enfortumab vedotin...
AbbVie lands FDA approval for Cerevel-origin Parkinson’s drug Juvmo
AbbVie (NYSE: ABBV) received US FDA approval for Juvmo (tavapadon) for the treatment of Parkinson's disease in adults, with the drug approved for use with...
UMass Chan, Mass General Brigham advance first gene therapy trial in mucolipidosis type IV
The US FDA has allowed an investigational new drug (IND) application to proceed for AAV-MCOLN1, an adeno-associated virus gene therapy for mucolipidosis...
Finland's Kasvu secures EUR 30m Series A for non-hallucinogenic depression drug
Finland-based Kasvu Therapeutics has raised EUR 30 million (USD 34.4 million) in a Series A financing to advance KTX-0141, a small-molecule TrkB positive...
Incyte/Mirum take FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva
The US FDA approved Atebrioz (zilurgisertib), an oral ALK2 inhibitor developed by Incyte (Nasdaq: INCY) and commercialized by Mirum Pharmaceuticals (Nasdaq:...
FDA keeps Newron’s ENIGMA-TRS 2 study on clinical hold
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5) said the US FDA’s clinical hold on new patient enrollment at US sites in the Phase III ENIGMA-TRS...
nChroma Bio's epigenetic silencer therapy shows sustained HBV suppression in preclinical models
Researchers at Boston-based genetic medicines company nChroma Bio published preclinical data in Nature Biomedical Engineering supporting CRMA-1001, an...
Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency
Cambridge, Massachusetts-based Prime Medicine, Inc. (Nasdaq: PRME) received US FDA clearance to begin first-in-human testing of PM647, a one-time in vivo...
Amplifyer Bio humanized priming agent boosts ctDNA recovery up to 100-fold in mice
Amplifyer Bio, an MIT and Broad Institute spinout developing agents designed to increase the amount of circulating tumor DNA (ctDNA) recoverable from blood,...
The AllSci Brief
Free, systematic R&D and deal news. Daily.